Autopsy report · NCT00434538

BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

“Due to Sponsor's financial reasons”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 9 months before it stopped.
• 40 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

BioSyntech Canada Inc.

Sponsor type

Industry

Conditions

Diabetic Foot Ulcer

Interventions

BST-DermOn

Participants

40

Sites

20

Countries

Canada

Trials that died the same way

• Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations
  “Due to the sponsor circumstances and external reasons” (93% match in meaning)
• Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS
  “Due to sponsor decision” (86% match in meaning)
• OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
  “Due to sponsor request” (81% match in meaning)
• Evaluation of Efficacy and Safety of Hyaluronic Acid (HA) Product for Cheek Augmentation
  “Sponsor business reasons” (79% match in meaning)
• Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
  “Due to financial reasons.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.